OFIX and SPNE announced a definitive agreement to combine in an all-stock merger of equals. Both companies believe there are meaninful cross-selling revenue synergies, as well as at least $40MM in YoY cost savings to capture over the 3 years following the transaction. The companies have expressed revenue goals of ~$1.0B concluding year 3 post-merger.

Looking forward, the new organization will be a spine and orthopedics company with complementary portfolios in biologics, spinal hardware, bone growth therapies, orthopedic solutions and enabling surgical technologies. SmartTRAK notes that once merged, the new company will be strategically positioned in high-growth emerging technology, including cervical disc replacement with M6-C, enabling technology with 7D’s FLASH Navigation System and OrthoNext preop planning, and with focused development in spine and limb within pediatrics. Additionally, the new company will have a highly competitive offering in the spinal interbody space with its WaveForm 3D and NanoMetalene technologies. Together, the combined company’s biologics portfolio will also represent one of the broadest offerings available in spine and orthopedics.

SmartTRAK believes the complimentary product portfolios provide a comprehensive offering and

 In an interview with SmartTRAK, Joel Gambrell, Co-founder and CEO for Astura Medical, shares the series of new products launching at NASS and, specifically, reveals what makes Astura’s new Integrated Expandable ALIF System, El Capitan, truly differentiated.

Since the Company was founded in 2014, Astura Medical has achieved fast growth, established a reputation for elegance and quality in its product offering and taken a different methodology to both product development and business operations. In an interview with SmartTRAK, Joel Gambrell, Co-founder and CEO, provides insight on how Astura’s R&D process is unique, unveils why Astura’s approach to custom implants offers the most real-time precision and reveals the distinctions that make the new Integrated Expandable ALIF System, El Capitan, truly differentiated. In addition to El Capitan, Astura Medical will be launching several other new technologies at the North American Spine Society’s (NASS) annual 2022 meeting in Chicago. 

SmartTRAK's spine experts will be roaming the floor at NASS 2022, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest news and innovations in the Spine Market and discuss how SmartTRAK can help you Be the Expert in your market.  If you would like to book a meeting with us at NASS, just click here.

Continue reading to find out how to download a complete transcript of SmartTRAK's interview with CEO Joel Gambrell.

With the North American Spine Society (NASS) 2022 annual meeting next week in Chicago, anticipation builds to see if some of the top players' product launches are unveiled at the event, including potential new offerings from Medtronic and NuVasive. Meanwhile, SmartTRAK expects to see bright spots from some of the pure-play companies like Centinel, Alphatec and Astura Medical. The event will surely be a pick-me-up from sluggish market performance plagued by budget constraints and supply chain issues. 

Our spine experts will be roaming the floor, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest in the spine market and discuss how SmartTRAK can help you Be the Expert in your market. To make sure you’re up to speed before the meeting, here is a sample of recent spine news collected and curated by the expert analysts at SmartTRAK. If you would like to book a meeting with us at NASS, please click the button below.

New Products:

• prodisc C* - Centinel Spine*
  

  Centinel Spine announced expansion of the prodisc cTDR portfolio. Currently, Centinel has 510(k) clearance for 1-level indications for prodisc C Vivo, prodisc C SK and prodisc C Nova giving them the broadest global offering in cTDR.

Spine enabling tech companies continue to report positive momentum moving into H222 despite limited hospital budgets, chip shortages and continued staffing issues. The North American Spine Society (NASS) 2022 annual meeting next week is sure to provide a preview of what is coming next for both spine robotics from players like Medtronic and Globus, as well as surgical guidance solution providers such as NuVasive and SeaSpine. We are also looking forward to new enabling tech solutions to be launched at the meeting.

Our spine experts will be roaming the floor, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest in the CAS Spine Market and discuss how SmartTRAK can help you Be the Expert in your market.

To make sure you’re up to speed before the meeting, here is a sample of recent CAS Spine news collected and curated by the expert analysts at SmartTRAK. If you would like to book a meeting with us at NASS, please click the button below. New Products:

• Stryker*
  

  SYK announced the launch of its Q Guidance System for spine applications, which includes surgical planning and intra-op guidance for spine procedures in patients age 13 and older.

Dr. Kim outlines his extensive experience in adopting endoscopic spine surgery and reflects on barriers to widespread adoption, including the learning curve and reimbursement challenges

Endoscopic and arthroscopic technology has been around for a number of years, aiding surgeons’ visualization to treat patients in much less invasive ways than were previously possible. Prior to the introduction and adoption of these types of technology, surgeons were faced with invasive, more traumatic procedures and sometimes limitations on visualization based on anatomy. Less invasive approaches have allowed patients to benefit from less risk, shorter hospital stays and, in many cases, quicker healing.

Endoscopic approaches to spine surgery have been taking place for 10+ years, but the market hasn’t experienced transformative growth. All the patient benefits align with relative adoption trends, so why haven’t we seen endoscopic spine surgery grow at a similar rate? What does the future look like in this segment? SmartTRAKsat down with minimally invasive spine surgery pioneer Choll Kim, MD, PhD to explore his thoughts on focusing his minimally invasive surgical practice around specific offering of endoscopic spinal techniques, what the pros and cons have been within the adoption curve of the technology and where he thinks the market is headed.

SmartTRAK's spine experts will be roaming the floor at NASS 2022, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest news and innovations in the Spine Market and discuss how SmartTRAK can help you Be the Expert in your market.  If you would like to book a meeting with us at NASS, please click here.

Continue reading to find out how to download a complete transcript of SmartTRAK's interview with Dr. Kim.

A market fraught with challenging hospital budgets, chip shortages and continued staffing issues results in apparent swings in robotic performance. On the other hand, enabling tech platforms companies continue to report positive momentum moving into H222.

The Q222 WW CAS Spine Market was down YoY according to SmartTRAK Financial Dashboard. Medtronic* (MDT) remained the market leader, followed by Globus* (GMED) and other enabling tech competitors including Stryker* (SYK) and Brainlab*. For detailed Q222 revenues and shares by company in the US, EU and ROW, see SmartTRAK CAS Spine Financial Dashboard*.

Among the many topics covered in detail in our comprehensive Q222 Computer Assisted Surgery Spine Market Recap* are:

• Complete Q222 CAS Spine Market Overview and Highlights
• SmartTRAK's Expert Analysis and Insights
• All Company News including Revenues, Data, Charts and Shares
• Variable Robotics Performance in a Difficult Climate

Among the many topics covered in detail in our comprehensive Q222 Extremities Market Recap* are:

John Uribe, MD, discusses inset glenoid technology and the future of shoulder replacement

John Uribe, MD, discusses his most recent research and experience with inset glenoids and how inset glenoids could influence the practice of shoulder replacement surgery. Dr. Uribe is a dual board-certified orthopedic surgeon with Baptist Health Group South Florida specializing in sports medicine, arthroscopic surgery and minimally invasive surgical procedures for degenerative knee, shoulder and elbow conditions. He is also the Chair of the Herbert Wertheim College of Medicine, Coral Gables, FL and the team physician for the Florida Panthers hockey team and the Miami Dolphins football team.

Dr. Uribe authored a study published in JSES International reporting results from 39 patients with advanced shoulder arthritis having anatomic shoulder replacement with the OVOMotion Shoulder Arthroplasty System from Anika, a stemless shoulder with an inlay glenoid component. The study demonstrated that treatment with inlay total shoulder arthroplasty resulted in significant functional improvement, pain relief and patient satisfaction at a mean follow-up of 41 months.

To find out more, including Dr. Uribe’s thoughts on the benefits of inlay glenoids vs onlay; the potential acceptance of inlay technology; trends such as the shift to reverse shoulders, site-of-care; and what’s next, click on the video below to listen to the recorded interview (17:36 min). A link to download a complete transcript of the interview is also provided below.

Despite stronger headwinds from slowing elective procedures, supply chain challenges and unfavorable foreign exchange rates, most total joint companies saw positive growth in Q222.

The WW Total Joints Market grew in Q222 despite slowing sequential growth compared to Q122’s growth. A slowdown in elective procedures late in the quarter along with continued supply chain challenges and the effect of foreign exchange rates resulted in stronger headwinds. SmartTRAK notes that several companies reported the carryover of these headwinds into Q3 that could dampen market recovery through year-end.

Among the many topics covered in detail in our comprehensive Q222 Total Joints Market Recap* are:

Q122 proved to be a mixed-bag of ups and downs with supply chain issues and Covid surges having varying impacts on market leaders’ performance amidst a strong wave of enabling tech product launches.

The Q122 WW CAS Ortho Market was down according to SmartTRAK Financial Dashboard. Stryker* remained the market leader, followed by Zimmer Biomet* and Smith & Nephew*. For detailed Q122 revenues and shares by company in the US, EU and ROW, see the SmartTRAK CAS Ortho Financial Dashboard.

Among the many topics covered in detail in our comprehensive Q122 CAS Ortho Market Recap* are: